image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 56.58
-3.96 %
$ 1.19 B
Market Cap
-120.38
P/E
1. INTRINSIC VALUE

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.[ Read More ]

The intrinsic value of one ANIP stock under the base case scenario is HIDDEN Compared to the current market price of 56.6 USD, ANI Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ANIP

image
FINANCIALS
487 M REVENUE
53.87%
47 M OPERATING INCOME
287.40%
18.8 M NET INCOME
139.21%
119 M OPERATING CASH FLOW
481.24%
-18.5 M INVESTING CASH FLOW
-17.62%
67.4 M FINANCING CASH FLOW
1415.63%
148 M REVENUE
7.46%
-20.5 M OPERATING INCOME
-371.18%
-22.4 M NET INCOME
-877.74%
12.5 M OPERATING CASH FLOW
-28.37%
-399 M INVESTING CASH FLOW
-8857.56%
291 M FINANCING CASH FLOW
20143.39%
Balance Sheet Decomposition ANI Pharmaceuticals, Inc.
image
Current Assets 520 M
Cash & Short-Term Investments 221 M
Receivables 162 M
Other Current Assets 137 M
Non-Current Assets 385 M
Long-Term Investments 0
PP&E 44.6 M
Other Non-Current Assets 340 M
Current Liabilities 145 M
Accounts Payable 36.7 M
Short-Term Debt 2.41 M
Other Current Liabilities 106 M
Non-Current Liabilities 301 M
Long-Term Debt 290 M
Other Non-Current Liabilities 11.7 M
EFFICIENCY
Earnings Waterfall ANI Pharmaceuticals, Inc.
image
Revenue 487 M
Cost Of Revenue 182 M
Gross Profit 305 M
Operating Expenses 196 M
Operating Income 47 M
Other Expenses 28.2 M
Net Income 18.8 M
RATIOS
62.71% GROSS MARGIN
62.71%
9.65% OPERATING MARGIN
9.65%
3.86% NET MARGIN
3.86%
4.34% ROE
4.34%
2.08% ROA
2.08%
6.18% ROIC
6.18%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis ANI Pharmaceuticals, Inc.
image
Net Income 18.8 M
Depreciation & Amortization 59.8 M
Capital Expenditures -18.5 M
Stock-Based Compensation 20.7 M
Change in Working Capital 24.9 M
Others 26.4 M
Free Cash Flow 100 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets ANI Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for ANIP of $81 , with forecasts ranging from a low of $60 to a high of $94 .
ANIP Lowest Price Target Wall Street Target
60 USD 6.04%
ANIP Average Price Target Wall Street Target
81 USD 43.16%
ANIP Highest Price Target Wall Street Target
94 USD 66.14%
4. DIVIDEND ANALYSIS
0.04% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership ANI Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
43.8 K USD 1
3-6 MONTHS
11.8 M USD 7
6-9 MONTHS
18.6 M USD 8
9-12 MONTHS
10.1 M USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
4 days ago
Nov 13, 2024
Sell 15.3 K USD
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
- 250
61.36 USD
1 month ago
Oct 14, 2024
Sell 14.3 K USD
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
- 250
57.19 USD
2 months ago
Sep 13, 2024
Sell 14.2 K USD
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
- 250
56.82 USD
3 months ago
Aug 13, 2024
Sell 14.9 K USD
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
- 250
59.62 USD
4 months ago
Jul 18, 2024
Sell 170 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 2743
62 USD
4 months ago
Jul 15, 2024
Sell 697 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 11000
63.38 USD
4 months ago
Jul 16, 2024
Sell 1.41 M USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 22000
64.27 USD
4 months ago
Jul 17, 2024
Sell 900 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 14257
63.16 USD
4 months ago
Jul 12, 2024
Sell 16.2 K USD
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
- 250
64.91 USD
4 months ago
Jul 01, 2024
Sell 1.27 M USD
Gassert Chad
SVP - CORP. DEV. & STRATEGY
- 20000
63.44 USD
4 months ago
Jun 21, 2024
Sell 1.18 M USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 20000
58.9 USD
5 months ago
Jun 17, 2024
Sell 488 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 7946
61.41 USD
5 months ago
Jun 18, 2024
Sell 644 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 10607
60.76 USD
4 months ago
Jun 20, 2024
Sell 685 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 11447
59.86 USD
5 months ago
Jun 13, 2024
Sell 16 K USD
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
- 250
63.8 USD
5 months ago
Jun 05, 2024
Sell 200 K USD
Gutwerg Ori
SVP, GENERICS
- 2985
67 USD
5 months ago
Jun 04, 2024
Sell 318 K USD
CAREY STEPHEN P.
SVP & CFO
- 5000
63.58 USD
5 months ago
Jun 03, 2024
Sell 1.29 M USD
Gassert Chad
SVP - CORP. DEV. & STRATEGY
- 20000
64.41 USD
5 months ago
May 21, 2024
Sell 123 K USD
Mutz Christopher
HEAD OF RARE DISEASE
- 2000
61.61 USD
5 months ago
May 20, 2024
Sell 795 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 12855
61.81 USD
6 months ago
May 15, 2024
Sell 978 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 14850
65.86 USD
6 months ago
May 16, 2024
Sell 1.05 M USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 16459
63.84 USD
6 months ago
May 17, 2024
Sell 362 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 5836
62.09 USD
6 months ago
May 16, 2024
Sell 128 K USD
TANNENBAUM RENEE P
Director
- 2000
63.87 USD
6 months ago
May 14, 2024
Sell 1.1 M USD
Lalwani Nikhil
PRESIDENT & CEO
- 16669
66.1 USD
6 months ago
May 13, 2024
Sell 16.9 K USD
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
- 250
67.69 USD
6 months ago
May 01, 2024
Sell 1.33 M USD
Gassert Chad
SVP - CORP. DEV. & STRATEGY
- 20000
66.62 USD
7 months ago
Apr 18, 2024
Sell 677 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 10423
64.98 USD
6 months ago
Apr 19, 2024
Sell 1.1 M USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 16809
65.17 USD
7 months ago
Apr 15, 2024
Sell 492 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 7414
66.33 USD
7 months ago
Apr 16, 2024
Sell 386 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 5834
66.2 USD
7 months ago
Apr 17, 2024
Sell 623 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 9520
65.4 USD
7 months ago
Apr 12, 2024
Sell 16.9 K USD
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
- 250
67.79 USD
7 months ago
Apr 01, 2024
Sell 1.34 M USD
Gassert Chad
SVP - CORP. DEV. & STRATEGY
- 20000
67.25 USD
8 months ago
Mar 13, 2024
Sell 16.6 K USD
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
- 250
66.54 USD
8 months ago
Mar 11, 2024
Sell 1.32 M USD
Gassert Chad
SVP - CORP. DEV. & STRATEGY
- 20000
65.81 USD
8 months ago
Mar 08, 2024
Sell 672 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 10000
67.17 USD
8 months ago
Mar 11, 2024
Sell 510 K USD
CAREY STEPHEN P.
SVP & CFO
- 7787
65.55 USD
8 months ago
Mar 06, 2024
Sell 1.9 M USD
Lalwani Nikhil
PRESIDENT & CEO
- 28965
65.52 USD
8 months ago
Mar 08, 2024
Sell 1.09 M USD
Lalwani Nikhil
PRESIDENT & CEO
- 16292
67.13 USD
8 months ago
Mar 07, 2024
Sell 1.62 M USD
Marken James G.
SVP OPS & PROD DEV
- 24338
66.37 USD
8 months ago
Mar 05, 2024
Sell 660 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 10093
65.35 USD
8 months ago
Mar 06, 2024
Sell 970 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 14822
65.47 USD
8 months ago
Mar 07, 2024
Sell 1 M USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 15085
66.35 USD
8 months ago
Mar 05, 2024
Sell 330 K USD
Mutz Christopher
HEAD OF RARE DISEASE
- 5000
66 USD
8 months ago
Mar 04, 2024
Sell 456 K USD
Pera Antonio R
Director
- 7000
65.2 USD
9 months ago
Feb 13, 2024
Sell 14 K USD
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
- 250
56.04 USD
9 months ago
Jan 19, 2024
Sell 251 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 4524
55.57 USD
9 months ago
Jan 22, 2024
Sell 318 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 5692
55.95 USD
9 months ago
Jan 23, 2024
Sell 847 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 15000
56.44 USD
10 months ago
Jan 16, 2024
Sell 278 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 5000
55.63 USD
10 months ago
Jan 17, 2024
Sell 551 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 10000
55.11 USD
9 months ago
Jan 18, 2024
Sell 541 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 9784
55.3 USD
10 months ago
Jan 12, 2024
Sell 14.1 K USD
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
- 250
56.43 USD
11 months ago
Dec 15, 2023
Sell 628 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 11974
52.44 USD
11 months ago
Dec 18, 2023
Sell 683 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 13026
52.44 USD
10 months ago
Dec 19, 2023
Sell 1.32 M USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 25000
52.65 USD
11 months ago
Dec 11, 2023
Sell 12.3 K USD
Cook Meredith
SR. VP, GENERAL COUNSEL & SEC.
- 250
49.21 USD
1 year ago
Nov 17, 2023
Sell 663 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 13000
51 USD
1 year ago
Nov 14, 2023
Sell 1.22 M USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 22905
53.17 USD
1 year ago
Nov 15, 2023
Sell 410 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 7647
53.64 USD
1 year ago
Nov 16, 2023
Sell 333 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 6448
51.66 USD
1 year ago
Nov 15, 2023
Sell 141 K USD
Davis Krista
SVP, CHIEF HR OFFICER
- 2622
53.81 USD
1 year ago
Nov 14, 2023
Sell 1.17 M USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 22095
53.17 USD
1 year ago
Nov 15, 2023
Sell 410 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 7647
53.64 USD
1 year ago
Nov 16, 2023
Sell 333 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 6448
51.66 USD
1 year ago
Nov 10, 2023
Sell 157 K USD
Mutz Christopher
HEAD OF RARE DISEASE
- 3000
52.47 USD
1 year ago
Oct 17, 2023
Sell 513 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 8758
58.53 USD
1 year ago
Oct 18, 2023
Sell 361 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 6242
57.78 USD
1 year ago
Oct 19, 2023
Sell 571 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 10000
57.06 USD
1 year ago
Oct 13, 2023
Sell 687 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 11937
57.58 USD
1 year ago
Oct 16, 2023
Sell 762 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 13063
58.31 USD
1 year ago
Oct 02, 2023
Sell 1.13 M USD
Gassert Chad
SVP - CORP. DEV. & STRATEGY
- 20000
56.48 USD
1 year ago
Sep 15, 2023
Sell 1.02 M USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 16242
62.81 USD
1 year ago
Sep 18, 2023
Sell 519 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 8425
61.64 USD
1 year ago
Sep 19, 2023
Sell 1.55 M USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 25333
61.23 USD
1 year ago
Sep 01, 2023
Sell 1.29 M USD
Gassert Chad
SVP - CORP. DEV. & STRATEGY
- 20000
64.7 USD
1 year ago
Aug 28, 2023
Sell 1.58 M USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 25000
63.06 USD
1 year ago
Aug 29, 2023
Sell 1.58 M USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 25000
63.37 USD
1 year ago
Aug 23, 2023
Sell 842 K USD
Gutwerg Ori
SVP, GENERICS
- 13502
62.39 USD
1 year ago
Aug 23, 2023
Sell 128 K USD
Gutwerg Ori
SVP, GENERICS
- 2059
62.39 USD
1 year ago
Aug 23, 2023
Sell 248 K USD
Marken James G.
SVP OPS & PROD DEV
- 3932
63 USD
1 year ago
Aug 16, 2023
Sell 11.7 M USD
MERIDIAN VENTURE PARTNERS II LP
10 percent owner
- 200000
58.5 USD
1 year ago
Aug 14, 2023
Sell 1.71 M USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 27890
61.15 USD
1 year ago
Aug 15, 2023
Sell 1.36 M USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 22110
61.6 USD
1 year ago
Aug 14, 2023
Sell 1.08 M USD
CAREY STEPHEN P.
SVP & CFO
- 17639
61.37 USD
1 year ago
Aug 14, 2023
Sell 181 K USD
Pera Antonio R
Director
- 3000
60.37 USD
1 year ago
Aug 11, 2023
Sell 3.27 M USD
Lalwani Nikhil
PRESIDENT & CEO
- 56666
57.75 USD
1 year ago
Aug 15, 2023
Sell 710 K USD
Lalwani Nikhil
PRESIDENT & CEO
- 11616
61.13 USD
1 year ago
Aug 01, 2023
Sell 1.02 M USD
Gassert Chad
SVP - CORP. DEV. & STRATEGY
- 20000
51.06 USD
1 year ago
Jul 19, 2023
Sell 307 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 5969
51.48 USD
1 year ago
Jul 20, 2023
Sell 309 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 6000
51.52 USD
1 year ago
Jul 21, 2023
Sell 604 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 11500
52.56 USD
1 year ago
Jul 14, 2023
Sell 504 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 10000
50.43 USD
1 year ago
Jul 17, 2023
Sell 502 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 9831
51.06 USD
1 year ago
Jul 18, 2023
Sell 347 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 6700
51.84 USD
1 year ago
Jul 03, 2023
Sell 1.07 M USD
Gassert Chad
SVP - CORP. DEV. & STRATEGY
- 20000
53.43 USD
1 year ago
Jun 20, 2023
Sell 761 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 14657
51.93 USD
1 year ago
Jun 21, 2023
Sell 615 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 11843
51.95 USD
1 year ago
Jun 22, 2023
Sell 694 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 13500
51.38 USD
1 year ago
Jun 23, 2023
Sell 515 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 10000
51.49 USD
1 year ago
Jun 22, 2023
Sell 1.03 M USD
Gassert Chad
SVP - CORP. DEV. & STRATEGY
- 20000
51.32 USD
1 year ago
Jun 20, 2023
Sell 761 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 14657
51.93 USD
1 year ago
Jun 21, 2023
Sell 615 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 11843
51.95 USD
1 year ago
Jun 22, 2023
Sell 694 K USD
Shanmugam Muthusamy
HEAD OF R&D, COO-NOVITIUM OPS
- 13500
51.38 USD
1 year ago
Dec 01, 2022
Sell 7.7 M USD
MERIDIAN VENTURE PARTNERS II LP
Director
- 200000
38.5 USD
2 years ago
Aug 12, 2022
Sell 195 K USD
Marken James G.
director: SVP OPS & PROD DEV
- 5172
37.7927 USD
2 years ago
Mar 21, 2022
Bought 200 K USD
Lalwani Nikhil
director: PRESIDENT & CEO
+ 7224
27.6851 USD
2 years ago
Mar 21, 2022
Bought 139 K USD
Walsh Patrick D
director:
+ 5000
27.7588 USD
2 years ago
Mar 18, 2022
Bought 139 K USD
Gassert Chad
director: SVP - CORP. DEV. & STRATEGY
+ 5000
27.8685 USD
2 years ago
Mar 17, 2022
Bought 138 K USD
Shanmugam Muthusamy
director: HEAD OF R&D, COO-NOVITIUM OPS
+ 5000
27.6503 USD
2 years ago
Dec 20, 2021
Bought 49.8 K USD
Thoma Jeanne
Director
+ 1072
46.4735 USD
2 years ago
Dec 07, 2021
Bought 127 K USD
Pera Antonio R
Director
+ 3000
42.2645 USD
2 years ago
Dec 06, 2021
Bought 98.4 K USD
HAUGHEY THOMAS
Director
+ 2500
39.38 USD
3 years ago
Mar 15, 2021
Bought 132 K USD
Walsh Patrick D
Director
+ 4000
32.8888 USD
4 years ago
Nov 09, 2020
Bought 130 K USD
Walsh Patrick D
Director
+ 5000
25.96 USD
4 years ago
Aug 10, 2020
Bought 92.7 K USD
Walsh Patrick D
CHAIRMAN, INTERIM PRES. & CEO
+ 3000
30.89 USD
4 years ago
Aug 10, 2020
Bought 124 K USD
Walsh Patrick D
CHAIRMAN, INTERIM PRES. & CEO
+ 4000
30.98 USD
4 years ago
Aug 10, 2020
Bought 91.2 K USD
Walsh Patrick D
CHAIRMAN, INTERIM PRES. & CEO
+ 3000
30.4 USD
4 years ago
Mar 04, 2020
Bought 135 K USD
HAUGHEY THOMAS
Director
+ 3000
45.05 USD
4 years ago
Mar 03, 2020
Bought 90.4 K USD
HAUGHEY THOMAS
Director
+ 2000
45.18 USD
5 years ago
Aug 19, 2019
Sell 141 K USD
MERIDIAN VENTURE PARTNERS II LP
10 percent owner
- 2067
68.3 USD
5 years ago
Aug 20, 2019
Sell 376 K USD
MERIDIAN VENTURE PARTNERS II LP
10 percent owner
- 5512
68.18 USD
5 years ago
Aug 19, 2019
Sell 141 K USD
MERIDIAN VENTURE PARTNERS II LP
10 percent owner
- 2067
68.3 USD
5 years ago
Aug 20, 2019
Sell 376 K USD
MERIDIAN VENTURE PARTNERS II LP
10 percent owner
- 5512
68.18 USD
5 years ago
Aug 14, 2019
Sell 1.84 M USD
MERIDIAN VENTURE PARTNERS II LP
10 percent owner
- 26360
69.89 USD
5 years ago
Aug 15, 2019
Sell 646 K USD
MERIDIAN VENTURE PARTNERS II LP
10 percent owner
- 9315
69.34 USD
5 years ago
Aug 16, 2019
Sell 1.79 M USD
MERIDIAN VENTURE PARTNERS II LP
10 percent owner
- 26349
68.09 USD
5 years ago
Aug 09, 2019
Sell 1.42 M USD
MERIDIAN VENTURE PARTNERS II LP
10 percent owner
- 19860
71.7 USD
5 years ago
Aug 12, 2019
Sell 1.5 M USD
MERIDIAN VENTURE PARTNERS II LP
10 percent owner
- 21016
71.45 USD
5 years ago
Aug 13, 2019
Sell 1.49 M USD
MERIDIAN VENTURE PARTNERS II LP
10 percent owner
- 20821
71.77 USD
5 years ago
May 24, 2019
Bought 99.4 K USD
NASH DAVID
Director
+ 1445
68.76 USD
5 years ago
May 17, 2019
Sell 629 K USD
Marken James G.
SVP Ops & Prod Dev
- 8907
70.67 USD
5 years ago
May 13, 2019
Sell 682 K USD
PRZYBYL ARTHUR
President and CEO
- 9595
71.1 USD
5 years ago
May 14, 2019
Sell 407 K USD
PRZYBYL ARTHUR
President and CEO
- 5772
70.45 USD
5 years ago
May 15, 2019
Sell 1.01 M USD
PRZYBYL ARTHUR
President and CEO
- 14633
69.25 USD
5 years ago
May 15, 2019
Bought 173 K USD
HAUGHEY THOMAS
Director
+ 2500
69.296 USD
5 years ago
May 14, 2019
Sell 346 K USD
Marken James G.
SVP Ops & Prod Dev
- 4917
70.31 USD
5 years ago
May 13, 2019
Sell 171 K USD
Schrepfer Robert W
SVP - New Bus Dev & Spec Sales
- 2409
71.13 USD
5 years ago
Mar 19, 2019
Sell 179 K USD
PRZYBYL ARTHUR
President and CEO
- 2823
63.51 USD
5 years ago
Mar 18, 2019
Sell 1.58 M USD
PRZYBYL ARTHUR
President and CEO
- 24802
63.53 USD
5 years ago
Mar 13, 2019
Sell 300 K USD
Schrepfer Robert W
SVP - New Bus Dev & Spec Sales
- 4651
64.4261 USD
5 years ago
Mar 12, 2019
Sell 364 K USD
Schrepfer Robert W
SVP - New Bus Dev & Spec Sales
- 5642
64.4414 USD
5 years ago
Mar 12, 2019
Sell 96.9 K USD
Schrepfer Robert W
SVP - New Bus Dev & Spec Sales
- 1503
64.5 USD
6 years ago
May 14, 2018
Sell 343 K USD
MARSHBANKS TRACY
Director
- 5506
62.35 USD
6 years ago
May 15, 2018
Sell 436 K USD
MARSHBANKS TRACY
Director
- 7024
62.05 USD
6 years ago
May 16, 2018
Sell 1.6 M USD
MARSHBANKS TRACY
Director
- 25706
62.4 USD
6 years ago
May 09, 2018
Sell 1.27 M USD
MARSHBANKS TRACY
Director
- 20517
62.05 USD
6 years ago
May 10, 2018
Sell 1.1 M USD
MARSHBANKS TRACY
Director
- 17685
62.14 USD
6 years ago
May 10, 2018
Sell 1.5 M USD
MARSHBANKS TRACY
Director
- 24229
62.03 USD
6 years ago
Apr 18, 2018
Sell 2.06 M USD
MARSHBANKS TRACY
Director
- 33200
62.09 USD
6 years ago
Mar 15, 2018
Sell 117 K USD
RAYNOR DANIEL
Director
- 1902
61.5 USD
6 years ago
Mar 19, 2018
Sell 322 K USD
RAYNOR DANIEL
Director
- 5313
60.62 USD
6 years ago
Mar 14, 2018
Sell 121 K USD
MARSHBANKS TRACY
Director
- 1912
63.1 USD
6 years ago
Mar 13, 2018
Sell 1.44 M USD
PRZYBYL ARTHUR
President and CEO
- 23475
61.52 USD
6 years ago
Mar 13, 2018
Sell 409 K USD
PRZYBYL ARTHUR
President and CEO
- 6525
62.63 USD
6 years ago
Mar 14, 2018
Sell 620 K USD
PRZYBYL ARTHUR
President and CEO
- 10000
62.03 USD
6 years ago
Mar 12, 2018
Sell 499 K USD
RAYNOR DANIEL
Director
- 7928
62.88 USD
6 years ago
Mar 13, 2018
Sell 865 K USD
RAYNOR DANIEL
Director
- 14000
61.81 USD
6 years ago
Mar 13, 2018
Sell 258 K USD
RAYNOR DANIEL
Director
- 4117
62.59 USD
6 years ago
Mar 14, 2018
Sell 119 K USD
RAYNOR DANIEL
Director
- 1919
62.02 USD
6 years ago
Mar 08, 2018
Sell 971 K USD
MARSHBANKS TRACY
Director
- 15391
63.08 USD
6 years ago
Mar 09, 2018
Sell 2.3 M USD
MARSHBANKS TRACY
Director
- 36561
63.01 USD
6 years ago
Mar 12, 2018
Sell 773 K USD
MARSHBANKS TRACY
Director
- 12269
63.03 USD
6 years ago
Mar 05, 2018
Sell 259 K USD
Marken James G.
SVP Ops & Prod Dev
- 4177
61.92 USD
6 years ago
Mar 01, 2018
Sell 332 K USD
Schrepfer Robert W
SVP - New Bus Dev & Spec Sales
- 5498
60.33 USD
6 years ago
Mar 01, 2018
Sell 666 K USD
Schrepfer Robert W
SVP - New Bus Dev & Spec Sales
- 10800
61.64 USD
6 years ago
Mar 01, 2018
Sell 744 K USD
Schrepfer Robert W
SVP - New Bus Dev & Spec Sales
- 11954
62.25 USD
6 years ago
Mar 01, 2018
Sell 25.2 K USD
Schrepfer Robert W
SVP - New Bus Dev & Spec Sales
- 400
63.07 USD
6 years ago
Mar 01, 2018
Sell 686 K USD
PRZYBYL ARTHUR
President and CEO
- 11326
60.59 USD
6 years ago
Mar 01, 2018
Sell 518 K USD
PRZYBYL ARTHUR
President and CEO
- 8400
61.62 USD
6 years ago
Mar 01, 2018
Sell 265 K USD
PRZYBYL ARTHUR
President and CEO
- 4260
62.17 USD
8 years ago
Aug 22, 2016
Sell 2.51 M USD
PRZYBYL ARTHUR
President and CEO
- 37455
66.97 USD
8 years ago
Aug 08, 2016
Sell 838 K USD
Schrepfer Robert W
VP Bus Dev & Con Mfg
- 12500
67.0567 USD
8 years ago
Dec 18, 2015
Sell 151 K USD
Marken James G.
Vice President, Operations
- 3500
43.26 USD
9 years ago
Nov 12, 2015
Bought 102 K USD
PRZYBYL ARTHUR
President and CEO
+ 2500
40.95 USD
9 years ago
Mar 19, 2015
Sell 998 K USD
Marken James G.
Vice President, Operations
- 15000
66.5 USD
9 years ago
Mar 12, 2015
Sell 9.04 M USD
MARSHBANKS TRACY
Director
- 143516
63 USD
9 years ago
Mar 12, 2015
Sell 3.67 M USD
MARSHBANKS TRACY
Director
- 58265
63 USD
9 years ago
Mar 12, 2015
Sell 377 K USD
MARSHBANKS TRACY
Director
- 5978
63 USD
9 years ago
Mar 12, 2015
Sell 141 K USD
MARSHBANKS TRACY
Director
- 2241
63 USD
9 years ago
Mar 12, 2015
Sell 2.84 M USD
Arnold Charlotte C.
Vice President and CFO
- 45000
63 USD
9 years ago
Mar 12, 2015
Sell 4.72 M USD
PRZYBYL ARTHUR
President and CEO
- 75000
63 USD
9 years ago
Mar 12, 2015
Sell 18.9 M USD
MERIDIAN VENTURE PARTNERS II LP
10 percent owner
- 300000
63 USD
7. News
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 2 days ago
ANI Pharmaceuticals, Inc. (ANIP) Q3 2024 Earnings Call Transcript ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q3 2024 Earnings Conference Call November 8, 2024 8:00 AM ET Company Participants Lisa Wilson - IR Nikhil Lalwani - President, CEO & Director Christopher Mutz - SVP, Head, Rare Diseases Stephen Carey - CFO & SVP Conference Call Participants David Amsellem - Piper Sandler Gary Nachman - Raymond James Vamil Divan - Guggenheim Securities Operator Good day, everyone, and welcome to today's ANI Pharmaceuticals Inc Third Quarter 2024 Earnings Results Call. Please note that this call is being recorded. seekingalpha.com - 1 week ago
Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 week ago
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.27 per share a year ago. zacks.com - 1 week ago
ANI Pharmaceuticals Reports Record Third Quarter 2024 Financial Results and Raises 2024 Guidance BAUDETTE, Minn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the three months ended September 30, 2024. globenewswire.com - 1 week ago
ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at at two upcoming investor conferences as follows: globenewswire.com - 1 week ago
Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago
ANI Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 8, 2024, at 8:00 a.m. ET PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to the market open. globenewswire.com - 2 weeks ago
ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06% PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Estradiol Gel, 0.06%. ANI's Estradiol Gel, 0.06% is the generic version of the reference listed drug (RLD) EstroGel® Gel, 0.06%. globenewswire.com - 3 weeks ago
ANI Pharmaceuticals to Present New Data Highlighting Membranous Nephropathy Research at American Society of Nephrology Kidney Week 2024 Two poster presentations demonstrate ANI's commitment to research in membranous nephropathy care Two poster presentations demonstrate ANI's commitment to research in membranous nephropathy care globenewswire.com - 3 weeks ago
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 3 weeks ago
Why Investors Need to Take Advantage of These 2 Medical Stocks Now Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. zacks.com - 1 month ago
8. Profile Summary

ANI Pharmaceuticals, Inc. ANIP

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 1.19 B
Dividend Yield 0.04%
Description ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Contact 210 Main Street West, Baudette, MN, 56623 https://www.anipharmaceuticals.com
IPO Date May 5, 2000
Employees 642
Officers Mr. Chad Gassert Senior Vice President of Corporate Development & Strategy Ms. Elizabeth Powell J.D. Chief Compliance Officer & Head of Legal of Rare Disease Ms. Meredith W. Cook J.D. Senior Vice President, General Counsel & Corporate Secretary Mr. Nikhil Lalwani President, Chief Executive Officer & Director Mr. Christopher K. Mutz Senior Vice President & Head of Rare Disease Ms. Krista L. Davis Senior Vice President & Chief Human Resources Officer Mr. Ori Gutwerg Senior Vice President of Generics Mr. James G. Marken Senior Vice President of Operations Mr. Stephen P. Carey Senior Vice President of Finance & Chief Financial Officer Mr. Muthusamy Shanmugam MS R.Ph. Head of R&D, Chief Operating Officer of Novitium Operations & Director